Prolonged SARS-CoV-2 Illness in a Patient Receiving Ocrelizumab for Multiple Sclerosis-Reference-Cited by-同舟云学术

Prolonged SARS-CoV-2 Illness in a Patient Receiving Ocrelizumab for Multiple Sclerosis

Published:2021-04-08 Issue:7 Volume:8 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Gibson Elena G¹,Pender Melissa²,Angerbauer Michael³,Cook Craig⁴,Jones Barbara⁴^ORCID,Spivak Adam M²,Spivak Emily S²⁵,Swaminathan Sankar²⁵^ORCID

Affiliation:

1. Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA

2. Division of Infectious Diseases, Department of Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA

3. School of Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA

4. Pulmonary and Critical Care, University of Utah School of Medicine, Salt Lake City, Utah, USA

5. Department of Medicine, George E. Wahlen Veterans Affairs Medical Center, Salt Lake City, Utah, USA

Abstract

Abstract We describe a case of prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in a patient receiving ocrelizumab for multiple sclerosis. Viral RNA shedding, signs, and symptoms persisted for 69 days with resolution after administration of convalescent plasma and antiviral therapy. This case suggests risk for persistent SARS-CoV-2 infection in patients treated with anti-CD-20 monoclonal antibodies and supports a role for humoral immunity in disease resolution.

Funder

NIH

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

http://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofab176/36977275/ofab176.pdf

Reference22 articles.

1. Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy;Helleberg;J Infect Dis,2020

2. Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer;Avanzato;Cell,2020

3. COVID-19 in persons with multiple sclerosis treated with ocrelizumab—a pharmacovigilance case series;Hughes;Mult Scler Relat Disord,2020